Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balaji Veeraraghavan

Showing results (1-10 of 348) with videos related to

Pageof 35
Sort By:
Msphere|August 4, 2025
Limitations of repurposing ceftazidime for <i>Stenotrophomonas maltophilia</i>: a cautionary perspectiveMadhumathi Irulappan, Balaji Veeraraghavan
Indian Journal of Medical Microbiology|June 29, 2025
Breakpoint Withdrawals and Emerging Evidence: Reframing Clinical Decisions for B. cepacia complex and S. maltophiliaBalaji Veeraraghavan, Kamini Walia
The Indian Journal of Medical Research|June 21, 2019
Antimicrobial susceptibility profile & resistance mechanisms of Global Antimicrobial Resistance Surveillance System (GLASS) priority pathogens from IndiaBalaji Veeraraghavan, Kamini Walia
Microbial Drug Resistance (Larchmont, N.Y.)|September 30, 2020
Decoding the Penicillin Resistance of <i>Streptococcus pneumoniae</i> for Invasive and Noninvasive InfectionsRosemol Varghese, Balaji Veeraraghavan
Indian Journal of Medical Microbiology|October 17, 2015
Advantage and limitations of nitrofurantoin in multi-drug resistant Indian scenarioLaishram Shakti, Balaji Veeraraghavan
Journal of Clinical and Diagnostic Research : JCDR|October 4, 2017
Challenges, Issues and Warnings from CLSI and EUCAST Working Group on Polymyxin Susceptibility TestingYamuna Devi Bakthavatchalam, Balaji Veeraraghavan
Annals of Clinical Microbiology and Antimicrobials|February 6, 2019
Accurate identification and epidemiological characterization of Burkholderia cepacia complex: an updateNaveen Kumar Devanga Ragupathi, Balaji Veeraraghavan
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 13, 2024
Re: 'Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates' by Poirel et alBalaji Veeraraghavan, Kamini Walia, Adrian Egli
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 20, 2024
Re: 'Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward' by tängdén et alBalaji Veeraraghavan, Kamini Walia, Adrian Egli
Future Science OA|July 10, 2019
Accurate identification of clinically important <i>Acinetobacter</i> spp.: an updateSaranya Vijayakumar, Indranil Biswas, Balaji Veeraraghavan
Pageof 35

Showing results (1-10 of 348) with videos related to

Sort By:
Pageof 35
Msphere|August 4, 2025
Limitations of repurposing ceftazidime for <i>Stenotrophomonas maltophilia</i>: a cautionary perspectiveMadhumathi Irulappan, Balaji Veeraraghavan
Indian Journal of Medical Microbiology|June 29, 2025
Breakpoint Withdrawals and Emerging Evidence: Reframing Clinical Decisions for B. cepacia complex and S. maltophiliaBalaji Veeraraghavan, Kamini Walia
The Indian Journal of Medical Research|June 21, 2019
Antimicrobial susceptibility profile & resistance mechanisms of Global Antimicrobial Resistance Surveillance System (GLASS) priority pathogens from IndiaBalaji Veeraraghavan, Kamini Walia
Microbial Drug Resistance (Larchmont, N.Y.)|September 30, 2020
Decoding the Penicillin Resistance of <i>Streptococcus pneumoniae</i> for Invasive and Noninvasive InfectionsRosemol Varghese, Balaji Veeraraghavan
Indian Journal of Medical Microbiology|October 17, 2015
Advantage and limitations of nitrofurantoin in multi-drug resistant Indian scenarioLaishram Shakti, Balaji Veeraraghavan
Journal of Clinical and Diagnostic Research : JCDR|October 4, 2017
Challenges, Issues and Warnings from CLSI and EUCAST Working Group on Polymyxin Susceptibility TestingYamuna Devi Bakthavatchalam, Balaji Veeraraghavan
Annals of Clinical Microbiology and Antimicrobials|February 6, 2019
Accurate identification and epidemiological characterization of Burkholderia cepacia complex: an updateNaveen Kumar Devanga Ragupathi, Balaji Veeraraghavan
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 13, 2024
Re: 'Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates' by Poirel et alBalaji Veeraraghavan, Kamini Walia, Adrian Egli
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 20, 2024
Re: 'Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward' by tängdén et alBalaji Veeraraghavan, Kamini Walia, Adrian Egli
Future Science OA|July 10, 2019
Accurate identification of clinically important <i>Acinetobacter</i> spp.: an updateSaranya Vijayakumar, Indranil Biswas, Balaji Veeraraghavan
Pageof 35